The Mexico Continuous Glucose Monitoring (CGM) market is forecast to grow at a CAGR of 12.8%, reaching USD 107.2 million in 2031 from USD 58.6 million in 2026.
Continuous sugar monitoring (CGM), sometimes referred to as continuous glucose monitoring, automatically monitors blood glucose throughout the day. Making more educated choices about maintaining daily medication use, a healthy diet, and physical activity can be aided with real-time glucose monitoring. A small sensor used in CGM is implanted beneath the skin, often on the arm or abdomen. The sensor picks up interstitial glucose, which is present in the intercellular fluid. The sensor examines the glucose level every few minutes, and wireless data transmission sends the results to a monitor.
Moreover, the closed-loop bionic/artificial pancreas has been given a blueprint because of CGMS-based technologies. Thus, businesses that manufacture glucose monitoring devices concentrate largely on creating novel and cutting-edge CGMS. It has several applications for healthcare settings (hospital ICUs, diagnostic centers, and clinics), for all age groups, and geographical locations. A growing awareness of diabetes preventative care, new product debuts, government efforts, and the CGM device market are the major market drivers for the CGM Market.
Throughout the projected period, technological developments to increase sensor accuracy are anticipated to fuel market expansion. IDF asserts that a range of socioeconomic, demographic, environmental, and genetic variables, such as urbanization, declining levels of physical activity, and rising rates of overweight and obesity, are to blame for the increase in type 2 diabetes cases in Mexico. For the convenience of diabetic patients, continuous glucose monitoring has grown to be a popular substitute for portable finger-prick glucometers already on the market in Mexico.
Increasing patients with Type-1 diabetes in Mexico is expected to surge in growth.
Mexico now ranks in the top 10 nations or territories in terms of total health expenditure, with diabetes-related medical costs exceeding USD 20 billion. Over half of the diabetics in the country (47.5%) have undiagnosed diabetes. If diabetes is not adequately diagnosed or managed, patients run the risk of serious and sometimes fatal consequences like heart attack, stroke, kidney failure, blindness, and lower limb amputation. As a result, people have a worse quality of life, spend more money on healthcare, and need access to treatment more frequently. Given that Type 2 diabetes is the top cause of mortality for women and the second leading cause of death for men in Mexico, it has become a burden on the healthcare system. Diabetes is a disease that can be brought on by obesity, sedentarism, bad eating habits, genetics, family history, and age. The aforementioned elements are thus anticipated to boost the Mexican market's expansion.
Better healthcare coverage by pharmacies to surge growth.
In Mexico, pharmacies are seen as a key instrument for improving healthcare coverage. Technology tools have been implemented in the pharmaceutical sector. Companies that participate in the "Beyond the Pills" campaign add digital platforms to their drug treatment programs to encourage follow-up and guarantee treatment continuation. One of the businesses utilizing the Beyond the Pills method to treat diabetes is Roche. MySugr is a digital platform used by the pharmaceutical business to control diabetes. To meet unmet requirements, Roche can do so by providing openly available patient solutions. It seeks to assist diabetics in improving their quality of life by helping them spend more time inside their optimum glucose target range.
In March 2023, the FDA approved the FreeStyle Libre 2 and FreeStyle Libre 3 modified CGM (continuous glucose monitoring) system sensors, as said by Abbott Laboratories, for connection with automated insulin delivery (AID) systems.
In November 2022, By offering in-office and at-home insertion options for the Eversense® E3 Continuous Glucose Monitoring System, Senseonics and Ascensia announced a collaboration with the nurse practitioner group (CGM).
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Companies |
|
Report Metric | Details |
Market Size Value in 2021 | US$32.027 million |
Market Size Value in 2028 | US$75.015 million |
Growth Rate | CAGR of 12.93% from 2021 to 2028 |
Base Year | 2021 |
Forecast Period | 2023 – 2028 |
Forecast Unit (Value) | USD Million |
Segments Covered | Application and End-User Industry |
Companies Covered | Dexcom, Inc., Abbott Laboratories, Medtronic plc[1], Roche Diabetes Care, Inc., Senseonics Holdings, Inc., Ascensia Diabetes Care, Insulet Corporation, Tandem Diabetes Care, Inc., GlySens Incorporated |
Customization Scope | Free report customization with purchase |
Mexico Continuous Glucose Monitoring (CGM) Market Segmentation:
By Application
Diabetes Patients
Critical Patients
By End-User Industry
Hospitals
Diagnostic Centers & Clinics
Home Care